To evaluate our hypothesis that targeting PSPC1 may enhance the anticancer activity of PARP inhibitors in BRCA-mutated breast or ovarian cancer, we initially analyzed the relationship between PSPC1 expression and olaparib sensitivity in 19 BRCA1/2-mutated ovarian cancer cell lines out of Genomics of Drug Sensitivity in Cancer (GDSC) data. This evidence concerns the gene PSPC1 and ovarian carcinoma.